NeoGenomics, Inc. (FRA:NG9)

Market Cap	1.31B -28.4%
Revenue (ttm)	604.42M +10.1%
Net Income	-96.71M
EPS	-0.76
Shares Out	n/a
PE Ratio	n/a
Forward PE	106.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	10.20
Previous Close	10.40
Day's Range	10.20 - 10.20
52-Week Range	4.20 - 14.40
Beta	n/a
RSI	44.92
Earnings Date	Feb 17, 2026

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on d...

• Industry: Medical Laboratories
• Founded: 2001
• Employees: 2,200
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NG9

Financial Performance

In 2024, NeoGenomics's revenue was $660.57 million, an increase of 11.65% compared to the previous year's $591.64 million. Losses were -$78.73 million, -10.51% less than in 2023.

Financial numbers in USD